Clinical trials: Hematologic Malignancy
Multiple Myeloma and Plasma Cell Neoplasm
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
- Trial name
- NCT00897910
- Testing
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Myeloid Leukemia, Chronic, Chronic-Phase
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).
- Trial name
- NCT00123474
- Testing
- dasatinib
- Where
- 137 sites in United States, Argentina and 29 more
- Volunteers
- 724 people
- Sponsor
- Bristol-Myers Squibb
Myeloid Neoplasm
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).
- Trial name
- NCT05656248
- Testing
- CPX-351, MHA, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving treosulfan together with fludarabine phosphate and total-body irradiation followed by donor stem cell transplant works in treating patients with high-risk acute myeloid leukemia…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00860574
- Testing
- treosulfan, fludarabine phosphate, total-body irradiation
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS)
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting…
- Conditions
- Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smouldering Myeloma
- Trial name
- LOOMIS (NCT03951220)
- Testing
- Diffusion Weighted Magnetic Resonance Imaging (DWMRI), DXA scan, Bloods and urine
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan…
- Trial name
- NCT00580372
- Testing
- VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Arkansas
Acute Myeloid Leukemia
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
- Trial name
- STIMULUS-AML1 (NCT04150029)
- Testing
- MBG453, Venetoclax, Azacitidine
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression.
- Trial name
- NCT01062230
- Testing
- Bortezomib (Velcade)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study is being conducted to learn about the effects of SC-PEG, which is a new form of a chemotherapy drug called asparaginase. Asparaginase is used to treat ALL and lymphoblastic lymphoma.
- Trial name
- NCT01574274
- Testing
- SC-PEG, Oncaspar
- Where
- 8 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia.
- Trial name
- NCT02971397
- Testing
- Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150091
- Testing
- Belantamab mafodotin, Nirogacestat, Lenalidomide
- Where
- 12 sites in United States, Brazil and 6 more
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
This study is being done because, despite major advances in therapy, MM is still considered an incurable disease. The purpose of this study is to determine the efficacy (how well it works) of the study treatment that combines the…
- Trial name
- NCT04113018
- Testing
- Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Wake Forest University Health Sciences
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and…
- Trial name
- NCT00142116
- Testing
- Thalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Steven P. Treon, MD, PhD
Anemia
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia.
- Trial name
- NCT00711958
- Testing
- HX575, solution for injection (s.c.), ERYPO®, Janssen-Cilag, solution for injection (s.c.)
- Where
- 19 sites in Germany, Romania
- Volunteers
- 114 people
- Sponsor
- Sandoz
Acute Myeloid Leukemia
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without any rest periods, until disease progression, relapse, intolerance to the drug, or elective allogeneic hematopoietic…
- Trial name
- ACE (NCT00989261)
- Testing
- Compound AC220
- Where
- 85 sites in United States, Canada and 7 more
- Volunteers
- 333 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
- Trial name
- SPARK-AML1 (NCT00952588)
- Testing
- AZD1152, LDAC
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Acute Leukemia, Chronic Lymphocytic Leukemia
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
This phase II trial studies how well tacrolimus, bortezomib, and anti-thymocyte globulin (thymoglobulin) work in preventing low toxicity graft versus host disease (GVHD) in patients with blood cancer who are undergoing donor stem…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02877082
- Testing
- Thymoglobulin, Bortezomib, Tacrolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.